Table 6.
Description of serological profile, treatment, and prevalence of adverse pregnancy outcome (APO) in the subgroups (all pregnancies included in the study).
| Serological profile |
||||
|---|---|---|---|---|
| O-APS, n = 124 (%) | T-APS, n = 66 (%) | NC-APS, n = 54 (%) | aPL carrier, n = 39 (%) | |
| Single aPL positivity | 75 (60.4) | 16 (24.2) | 32 (59.2) | 21(53.8) |
| Double aPL positivity | 20 (16.1) | 14 (21.2) | 11(20.3) | 10 (25.6) |
| Triple aPL positivity | 29 (23.3) | 36 (54.5) | 11(20.3) | 8 (20.6) |
| Treatment | ||||
| LDA monotherapy | 17 (13.7) | 1 (1.5) | 23 (42.6) | 26 (66.6) |
| LMWH monotherapy | 0 (0) | 5 (7.5) | 0 (0) | 0 (0) |
| Combination treatment (LDA + LMWH) prophylactic dose | 97 (78.2) | 21 (31.2) | 31 (57.4) | 12 (30.8) |
| Combination treatment (LDA + LMWH) therapeutic dose | 10 (8) | 39 (59.1) | 0 (0) | 1 (2.6) |
| Hydroxychloroquine | 8 (6.4) | 19 (28.8) | 3 (5.5) | 2 (5.1) |
| Steroids | 4 (3.2) | 9 (13.6) | 3 (5.5) | 4 (10.2) |
|
APOa |
||||
| O-APS, n = 22 (17.7%) | T-APS, n = 16 (24.2%) | NC-APS, n = 5 (9.2%) | aPL carrier, n = 7 (17.9%) | |
| Spontaneous abortion | 9 (41) | 8 (50) | 2 (40) | 1 (14.2) |
| Fetal death | 4 (18.2) | 4 (25) | 1 (20) | 3 (42.8) |
| Neonatal death due to prematurity | 0 (0) | 0 (0) | 0 (0) | 1 (14.2) |
| Preterm deliveries <34 weeks | 7 (31.8) | 4 (25) | 2 (40) | 3 (42.8) |
| Small for gestational age associated with abnormal Doppler flow velocimetry | 2 (9) | 0 (0) | 1(20) | 1 (14.2) |
| Hemolysis, elevated liver enzymes, and low platelets | 2 (9) | 3 (18.7) | 0 (0) | 2 (28.5) |
LDA, low-dose aspirin; LMWH, low-molecular-weight heparin.
aThe same patient can be included in more than one category.